Insulin detemir: A historical perspective on a modern basal insulin analogue.
Insulin detemir provides prolonged, reproducible blood glucose reduction through a mechanism unique among basal insulins. It was originally studied clinically in predominantly basal + bolus regimens and found to be associated with a low risk of hypoglycaemia compared to insulin NPH, and reduced weight gain compared to other basal insulins. Insulin detemir has been increasingly studied in basal-only insulin regimens in type 2 diabetes, in which an understanding of how to optimize its use has been built incrementally. Glycaemic control and limitation of weight gain tend to be maximized by once-daily (evening) dosing, earlier initiation and careful titration to appropriate fasting glucose targets.
Meneghini
Luigi
L
University of Miami Miller School of Medicine, Florida 33136, USA.
Liebl
Andreas
A
Abrahamson
Martin J
MJ
D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy / Q000266:history*; D049673:History, 20th Century; D049674:History, 21st Century; D006801:Humans; D007004:Hypoglycemic Agents / Q000266:history* / Q000627:therapeutic use; D007328:Insulin / Q000031:analogs & derivatives* / Q000266:history / Q000627:therapeutic use; D000069057:Insulin Detemir; D049528:Insulin, Long-Acting
D007004:Hypoglycemic Agents; D007328:Insulin; D049528:Insulin, Long-Acting; D000069057:Insulin Detemir